CDKN2B and cancer: FGF-2-mediated cell cycle inhibition and dormancy through TGFβ1, p21Waf1, p15INK4b, p27Kip1, motility inhibition through FGF-2- and integrin α5β1-mediated RhoA inhibition and actin-rearrangement in cancer cells, treatment resistance through PI3K/AKT